---
schema_version: "secwatch.filing_event.v1"
accession: "0001638833-22-000017"
form_type: "8-K"
ticker: "SGRY"
cik: "0001638833"
company_name: "Surgery Partners, Inc."
filed_at: "2022-02-28T23:59:59+00:00"
generated_at: "2026-06-27T03:40:48.473645+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Surgery Partners Q4 2021 Adj. EBITDA $114.4M, raises 2022 guidance

## Summary
- Q4 2021 revenue $610.2M (+11.3% YoY); net loss $0.1M; Adj. EBITDA $114.4M (+26.0%, incl. $11.6M CARES grants).
- Full-year 2021 revenue $2.225B (+19.6% YoY); Adj. EBITDA $339.6M (+32.3%, incl. $25.3M CARES grants).
- Days adjusted same-facility revenue +9.6% in Q4; case volume +4.2%. Full-year same-facility revenue +18.1%.
- 2022 guidance: revenue at least $2.5B (+12% YoY); Adj. EBITDA $370-380M, raised from prior outlook.
- Cash $389.9M at Dec. 31; total net debt/EBITDA leverage 5.58x; capital deployment target at least $200M annually.

## SEC filing metadata
- accession: 0001638833-22-000017
- form_type: 8-K
- ticker: SGRY
- cik: 0001638833
- company_name: Surgery Partners, Inc.
- filed_at: 2022-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638833/000163883322000017/0001638833-22-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638833/000163883322000017/sgry-20220228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001638833-22-000017
- JSON: https://secwatch.observer/filing/0001638833-22-000017.json
- Plain text: https://secwatch.observer/filing/0001638833-22-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.